The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's (ADAP.O), opens new tab first-of-its-kind treatment for a rare type of cancer in the soft tissues that most often affects young people. Tecelra, a one-time intravenous therapy, modifies and uses a patient's own immune response generating T-cells to fight the disease. The treatment carries a list price of $727,000, the company said. Source: Reuters 5/8/2024